9 results about "Terlipressin" patented technology

A method for treating ascites patients by administering the peptide drug terlipressin by continuous infusion. The patients include those whose ascites condition has not progressed to hepatorenal syndrome (HRS). Administration may be accomplished with a continuous infusion pump.

Methods are disclosed of treating or preventing hypotension (e.g., neurogenic orthostatic hypotension or postprandial hypotension) or portal hypertension (e.g., bleeding esophageal varices associated with portal hypertension) or ascites (e.g., ascites associated with liver cirrhosis), by oral administration to affected subjects of compositions comprising a therapeutically effective amount of terlipressin or a pharmaceutically acceptable salt thereof.

The invention belongs to the field of biological medicine, and particularly relates to a 12-bit deamination esterification impurity of terlipressin for injection and application. The deamination and esterification impurity is a terlipressin 12-site deamination and esterification compound generated by reaction of terlipressin 12-site amination glycine and mannitol, the molecular weight of a single isotope is 1391.5510, and the structural formula of the deamination and esterification impurity is shown as a formula I. The deamination and esterification impurity is a terlipressin 12-site deamination and esterification compound.

The invention belongs to the field of biological medicine, and particularly relates to an impurity detection method of a terlipressin preparation for injection. The impurity is the deamination esterification impurity of terlipressin and mannitol found for the first time, the structure of the impurity is shown as a formula I and / or a formula II, and the synthesized impurity is used as a reference substance and is detected through ultra-high performance liquid chromatography.

The invention belongs to the field of biological medicine, and particularly relates to esterified impurities of terlipressin and mannitol and application of the esterified impurities. The alcohol esterification impurity is a terlipressin mannitol esterification compound generated by deamination and esterification reaction of the 8th asparagine of terlipressin and mannitol, the single isotope molecular weight of the alcohol esterification impurity is 1391.5510, and the structural formula of the alcohol esterification impurity is as shown in the formula I. The alcohol esterification impurity is a terlipressin mannitol esterification compound.

The application discloses a lyophilized preparation of terlipressin acetate and a preparation method thereof. The lyophilized preparation of terlipressin acetate comprises terlipressin acetate, an excipient, a stabilizer and water. The weight ratio of the terlipressin acetate and the excipient is 1:(8-18), the weight ratio of the terlipressin acetate and the stabilizer is 1:(1-2), and the weight ratio of the terlipressin acetate and water is 1:(4000-6000). The excipient is modified dextran. The application aims at solving the technical problem of poor stability of terlipressin.

A method for treating diseases with arginine vasopressin or its analogues is provided, which reduces the risk of hyponatremia.Specifically, the present invention relates to the novel observation that subjects receiving terlipressin and gabapentin or pregabalin in combination have a high incidence of severe hyponatremia.The method of the present invention includes either removing subjects receiving gabapentin, gabapentin analogues, gabapentinoids, and other drugs known to cause hyponatremia from arginine vasopressin or its analogues treatment, or reducing the dose of gabapentin, gabapentin analogues, gabapentinoids, and other drugs known to cause hyponatremia to the subject before administering arginine vasopressin or its analogues, or stopping the administration of gabapentin, gabapentin analogues, gabapentinoids, and other drugs known to cause hyponatremia during the administration of arginine vasopressin or its analogues, or reducing the dose of arginine vasopressin or its analogues.

The disclosure provides pharmaceutical compositions comprising terlipressin having increased concentration with long term storage stability.

Methods of treating ascites patients by administering the polypeptide drug terlipressin via continuous infusion. The patients include those whose ascites conditions have not developed to hepatorenal syndrome (HRS). Administration may be effected with a continuous infusion pump.